Sotac Pharmaceuticals Valuation
Is SOTAC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of SOTAC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate SOTAC's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate SOTAC's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SOTAC?
Other financial metrics that can be useful for relative valuation.
| What is SOTAC's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | ₹1.31b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.5x |
| Enterprise Value/EBITDA | 17.4x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does SOTAC's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 31.4x | ||
524652 Ind-Swift | 3x | n/a | ₹1.2b |
531398 Source Natural Foods and Herbal Supplements | 79.8x | n/a | ₹1.5b |
538964 Mercury Laboratories | 23x | n/a | ₹1.1b |
530233 Auro Laboratories | 19.7x | n/a | ₹1.5b |
SOTAC Sotac Pharmaceuticals | 29.4x | n/a | ₹1.3b |
Price-To-Earnings vs Peers: SOTAC is good value based on its Price-To-Earnings Ratio (29.4x) compared to the peer average (31.4x).
Price to Earnings Ratio vs Industry
How does SOTAC's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?
Price-To-Earnings vs Industry: SOTAC is good value based on its Price-To-Earnings Ratio (29.4x) compared to the Indian Pharmaceuticals industry average (37.6x).
Price to Earnings Ratio vs Fair Ratio
What is SOTAC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 29.4x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate SOTAC's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.